MSD wins key EU approval for Keytruda, Alimta combo

MSD wins key EU approval for Keytruda, Alimta combo. Decision keeps Keytruda well ahead of rival Tecentriq. ... Compared to those on Alimta and chemotherapy alone, there was a 51% reduction in risk of death for those treated with Keytruda in combination

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

For years, Lilly’s presence in cancer has been led by lung cancer chemotherapy drug Alimta (pemetrexed), which brought in $2bn in sales last year but has been gradually declining from

Roche eyes September FDA verdict for triple NSCLC therapy

of carboplatin and Celgene’s Abraxane (nab-paclitaxel) and Eli Lilly’s Alimta (pemetrexed) in first-line non-squamous NSCLC – IMpower130 and IMpower132 respectively, with results due in the coming months.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)